Tirzepatide
Tirzepatide is a fatty-acid-modified peptide studied as a dual GIP and GLP-1 receptor agonist. Approved business buyers can apply for wholesale access.
US Peptide Distributors supplies Tirzepatide at wholesale to approved business buyers in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 80mg and 100mg vials, from USA stock with same-day shipping and overseas-sourced supply (typically 7-10 days). Every lot is tested by an independent third-party laboratory (we use Freedom Diagnostics and ILS Labs): HPLC for purity and mass spectrometry for identity. There is no minimum order on USA stock. Pricing is quoted by supply option and tiered by volume.
Updated
- Synonyms
- LY3298176
- Formula
- C225H348N48O68
- Molecular weight
- 4813 g/mol
- CAS number
- 2023788-19-2
Approved buyers see pricing
Wholesale pricing is available to approved business buyers after they log in.
Supply and testing
- Every lot third-party testedHPLC for purity, mass spectrometry for identity. Labs: Freedom Diagnostics and ILS Labs.
- Three supply optionsSupply options for wholesale ordersUSA stock (ships from US inventory), USA-synthesized, overseas-sourced.Ask which options apply to this compound.
- Same-day shipping on USA stockExpedited options available. Overseas-sourced orders typically take 7-10 days.
- No minimum on USA stockOne box to thousands of kits, plus gram and kilogram powder.
- COA in your company nameCan be added to an order and is provided with it.
Distributor programShipping times
Request a quote for TirzepatideWhat the molecule is
Tirzepatide (development code LY3298176) is a synthetic peptide with a fatty acid attached. Its formula is C225H348N48O68 and PubChem gives the molecular weight as about 4,813 g/mol. The point of interest to receptor pharmacologists is that a single molecule engages two incretin receptors, the receptor for glucose-dependent insulinotropic polypeptide (GIPR) and the receptor for glucagon-like peptide-1 (GLP-1R). Researchers call this class dual agonists, or co-agonists.
Signaling studies
The most cited mechanistic work is a 2020 paper from Lilly and academic collaborators. They built a method for estimating how much of each receptor the molecule occupies and concluded that engagement is greater at GIPR than at GLP-1R, which is why the title calls it imbalanced. They also compared its signaling with the natural hormones. At GIPR, the molecule behaved much like native GIP. At GLP-1R it was biased: it favored cAMP generation over recruitment of the scaffold protein beta-arrestin, and it drove less receptor internalization than GLP-1 did. In primary islet experiments, beta-arrestin1 limited the response to GLP-1 but not to GIP or to tirzepatide.
Structural work
A 2022 study in PNAS added cryo-electron microscopy and molecular dynamics simulations to explain those signaling differences at the atomic level. It found that the peptide activates GIPR in a way that closely resembles native GIP, yet differs substantially from GLP-1 in how it activates GLP-1R, with less agonist-induced desensitization. The authors concluded that the fatty acid modification and the amino acid sequence together determine the mode of action of a multireceptor agonist, an observation that is useful when comparing it with single-target relatives such as semaglutide.
Analytical considerations
Several PubChem records exist for this substance, reflecting differences in how stereochemistry is drawn, but they share the same formula, weight and CAS number. For quality work the relevant questions are whether the intact mass matches the formula, whether the lipid side chain is attached at the intended residue, and how counterions and water contribute to the weighed material. Our guide on purity, net content and counterions covers the last of those in detail.
Scope of this page
This page covers molecular identity and receptor-pharmacology research. It does not discuss use in people. Supply is for approved business buyers, for laboratory research use only.
References
Questions
Is tirzepatide an approved drug?
Tirzepatide is the active ingredient of a drug approved by FDA. On 2026-04-30 FDA proposed excluding tirzepatide, along with semaglutide and liraglutide, from the 503B bulks list.
What is the wholesale cost of tirzepatide?
Pricing is shown only to approved business accounts after login, and this page does not list prices. Businesses can apply for an account on the apply page.
Where can I buy Tirzepatide in bulk?
US Peptide Distributors supplies Tirzepatide to approved business buyers in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 80mg and 100mg vials, from USA stock with same-day shipping and overseas-sourced supply (typically 7-10 days). Apply for a buyer account to see wholesale pricing; larger volumes are quoted on request.
Is each lot of Tirzepatide third-party tested?
Yes. Every lot US Peptide Distributors supplies is tested by an independent third-party laboratory (we use Freedom Diagnostics and ILS Labs): HPLC for purity and mass spectrometry for identity. Lot COAs appear on this page as they are uploaded.
What is tirzepatide chemically?
Tirzepatide (development code LY3298176) is a fatty-acid-modified synthetic peptide with the formula C225H348N48O68 and a molecular weight of about 4,813 g/mol. It acts as a dual GIP and GLP-1 receptor agonist.
Is tirzepatide sold for use in humans?
No. It is sold to approved business buyers for laboratory research use only, not for use in humans.
Can I buy Tirzepatide from a US supplier?
Yes. US Peptide Distributors holds Tirzepatide in USA stock, which ships from US inventory with same-day shipping and expedited options available. There is no minimum order on USA stock.